Shenzhen Neptunus Bioengineering Co., Ltd.

000078.SZ

000078.SZShenzhen Neptunus Bioengineering Co., Ltd.

Shenzhen

2.14

CNY

-0.01

(-0.47%)

-0.66EPS

-3.24P/E

5.37BMarket Cap

Oct 29Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

CNE000000X95

Return %

Stock

S&P500

-29.61

24.79

-35.15

26.53

-40.39

87.24

Use logarithmic scale

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	3.25	3.93	4.49	5.36	15.19	6.13	9.42	14.51	15.68	15.26	15.62	14.39	13.84	12.57
Basic EPS, GAAP	0.03	0.04	0.07	0.01	0.65	0.19	0.24	0.17	0.08	-0.11	0.04	-0.39	-0.64	-0.66
Free Cash Flow per Basic Share	-0.18	-0.15	-0.23	-0.19	-0.11	-0.8	-1.02	-0.51	0.79	0.57	0.28	-0.06	-0.2	-0.04
Dividend per Share	0.07	0.09	0.09	0.12	0.39	0.09	0.06	0.41	0.51	0.29	0.22	0.25	0.21	0.2
Book Value per Share	-0.18	-0.15	-0.02	-0.01	0.65	1.26	1.22	1.38	1.49	1.39	1.42	1.03	0.39	0.4
Tangible Book Value per Share	0.45	0.48	0.87	0.78	2.33	2.27	0.95	1.09	1.56	1.76	1.69	1.46	1.1	1.11
Basic Weighted Avg Shares	1,631	1,632	1,780	1,830	732	2,221	2,648	2,646	2,646	2,623	2,628	2,630	2,631	2,632
Sales/Revenue/Turnover	5,305	6,418	7,993	9,802	11,118	13,606	24,940	38,381	41,493	40,022	41,054	37,835	36,419	33,096
Operating Margin (%)	4.28	3.59	3.41	3.73	4.39	5.97	6.43	5.1	5.58	4.57	3.83	2.67	2.43	2.28
Depreciation Expense	53	61	70	87	80	75	103	131	152	194	269	276	284	- -
Net Income, GAAP	53	59	117	24	475	418	639	448	206	-289	93	-1,027	-1,690	-1,732
Effective Tax Rate (%)	38.1	6.57	34.17	46.64	17.6	23.7	28.78	30.82	41.25	115.44	55.26	- -	- -	158.21
Profit Margin (%)	0.99	0.92	1.46	0.24	4.27	3.08	2.56	1.17	0.5	-0.72	0.23	-2.71	-4.64	-5.23
Working Capital	-15	-73	509	154	740	3,696	2,350	3,058	2,742	1,677	1,855	1,831	1,081	1,161
LT Debt	- -	- -	- -	- -	- -	24	1,703	3,374	1,359	357	377	400	320	386
Total Equity	971	1,057	1,888	1,783	2,143	5,878	6,470	7,158	7,851	7,490	7,308	6,112	4,217	4,250
Return on Invested Capital (%)	5.74	7.53	4.85	4.48	8.47	9.34	10.81	8.13	6.54	-1.3	3.33	- -	- -	- -
Return on Capital (%)	8	8.7	4.47	1.99	19.11	10.71	8.92	5.72	3.36	-3.56	1.7	- -	- -	55.55
Return on Common Equity (%)	- -	- -	- -	- -	- -	25.63	21.27	13.02	5.43	-7.61	2.53	-31.86	-90.6	-89.7

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	19.12%	-0.89%	-3.74%
Net Income, GAAP	26.45%	-312.46%	64.56%
Free Cash Flow	181.05%	-46.52%	224.16%
Total Cash Common Dividend	50.56%	-8.91%	-14.55%
Total Equity	16.49%	-8.94%	-31%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Feng Zhang
Full Time Employees: 9,093
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: Wang Yinhe Technology Building Shenzhen People's Republic of China 518057
IPO Date: Invalid Date
Website: www.neptunus.com
Business: Shenzhen Neptunus Bioengineering Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products primarily in China. It offers drugs in the fields of anti-tumor, cardio-cerebrovascular, marine drugs, and other fields. The company was founded in 1989 and is based in Shenzhen, China.

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	3.25	3.93	4.49	5.36	15.19	6.13	9.42	14.51	15.68	15.26	15.62	14.39	13.84	12.57
Basic EPS, GAAP	0.03	0.04	0.07	0.01	0.65	0.19	0.24	0.17	0.08	-0.11	0.04	-0.39	-0.64	-0.66
Free Cash Flow per Basic Share	-0.18	-0.15	-0.23	-0.19	-0.11	-0.8	-1.02	-0.51	0.79	0.57	0.28	-0.06	-0.2	-0.04
Dividend per Share	0.07	0.09	0.09	0.12	0.39	0.09	0.06	0.41	0.51	0.29	0.22	0.25	0.21	0.2
Book Value per Share	-0.18	-0.15	-0.02	-0.01	0.65	1.26	1.22	1.38	1.49	1.39	1.42	1.03	0.39	0.4
Tangible Book Value per Share	0.45	0.48	0.87	0.78	2.33	2.27	0.95	1.09	1.56	1.76	1.69	1.46	1.1	1.11
Basic Weighted Avg Shares	1,631	1,632	1,780	1,830	732	2,221	2,648	2,646	2,646	2,623	2,628	2,630	2,631	2,632
Sales/Revenue/Turnover	5,305	6,418	7,993	9,802	11,118	13,606	24,940	38,381	41,493	40,022	41,054	37,835	36,419	33,096
Operating Margin (%)	4.28	3.59	3.41	3.73	4.39	5.97	6.43	5.1	5.58	4.57	3.83	2.67	2.43	2.28
Depreciation Expense	53	61	70	87	80	75	103	131	152	194	269	276	284	- -
Net Income, GAAP	53	59	117	24	475	418	639	448	206	-289	93	-1,027	-1,690	-1,732
Effective Tax Rate (%)	38.1	6.57	34.17	46.64	17.6	23.7	28.78	30.82	41.25	115.44	55.26	- -	- -	158.21
Profit Margin (%)	0.99	0.92	1.46	0.24	4.27	3.08	2.56	1.17	0.5	-0.72	0.23	-2.71	-4.64	-5.23
Working Capital	-15	-73	509	154	740	3,696	2,350	3,058	2,742	1,677	1,855	1,831	1,081	1,161
LT Debt	- -	- -	- -	- -	- -	24	1,703	3,374	1,359	357	377	400	320	386
Total Equity	971	1,057	1,888	1,783	2,143	5,878	6,470	7,158	7,851	7,490	7,308	6,112	4,217	4,250
Return on Invested Capital (%)	5.74	7.53	4.85	4.48	8.47	9.34	10.81	8.13	6.54	-1.3	3.33	- -	- -	- -
Return on Capital (%)	8	8.7	4.47	1.99	19.11	10.71	8.92	5.72	3.36	-3.56	1.7	- -	- -	55.55
Return on Common Equity (%)	- -	- -	- -	- -	- -	25.63	21.27	13.02	5.43	-7.61	2.53	-31.86	-90.6	-89.7

	Dec'23	Mar'24	Jun'24
Total Current Assets	28,809	29,072	28,253
Accounts Receivable, Net	17,357	17,364	16,773
Cash, Cash Equivalents & STI	3,675	3,932	4,126
Inventories	3,679	3,465	3,498
Total Current Liabilities	27,728	28,014	27,091
Payables & Accruals	- -	- -	- -
ST Debt	11,078	11,038	10,671
Deferred Revenue	- -	- -	- -

	Dec'23	Mar'24	Jun'24
ST Debt	11,078	11,038	10,671
LT Borrowings	200	209	260
LT Finance Leases	120	146	125
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	2,751	2,751	2,751
Market Capitalization	8,636	6,396	5,580

Year	Q1	Q2	Q3	Q4	FY
2022	9,202	8,920	10,834	8,879	37,835
2023	9,958	9,996	8,687	7,778	36,419
2024	8,088	8,544	- -	- -	- -

Shenzhen Neptunus Bioengineering Co., Ltd.

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Working Capital

Capital Structure

Quarterly Earnings Per Share

Year

Quarterly Dividends Per Share

Year

Quarterly Revenue

Year